Pfizer Inc. Q2 FY2026 Earnings Call Summary

PFE NYSE Healthcare 📅 2026-08-04 ⏱ ~60 sec read 🟡 Neutral

⏱️ 60-Second Brief Pfizer Inc. · Q2 FY2026

Revenue

$15.0B

EPS

$0.77

AI Sentiment

🟡 Neutral

While a reported net loss due to impairments is a concern, s…

📌 Bottom Line: Pfizer reported second-quarter 2026 revenues of $15.0 billion, reflecting 1% operational year-over-year growth, alongside an adjusted diluted EPS of $0.77, despite a reported net loss of $248 million primarily due to int…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-08-04 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Pfizer reported second-quarter 2026 revenues of $15.0 billion, reflecting 1% operational year-over-year growth, alongside an adjusted diluted EPS of $0.77, despite a reported net loss of $248 million primarily due to intangible asset impairments. The company raised its full-year revenue guidance and announced significant new cost-saving initiatives, signaling confidence in its non-COVID product portfolio and future profitability despite ongoing challenges with its pandemic-related offerings.

📊 Key Financial Metrics

Revenue $15.0B

EPS (Diluted) $0.77

YoY Revenue Growth 1%

Gross Margin 75.7%

Net Income -$248M

AI Sentiment 🟡 Neutral While a reported net loss due to impairments is a concern, strong operational growth in non-COVID products, raised revenue guidance, and aggressive cost-saving initiatives balance the outlook, suggesting a company in transition with clear strategic direction.

✅ What Went Well

✅ Exceptional operational growth in launched and acquired products, which collectively grew 18% year-over-year, highlighting successful portfolio diversification and strong market uptake for newer therapies.

✅ Robust underlying business performance, with revenues growing 5% operationally when excluding the declining contributions from COVID-19 products (Comirnaty and Paxlovid).

✅ Raised the midpoint of full-year 2026 revenue guidance by $500 million, signaling management's increased confidence in the performance of its non-COVID product portfolio.

⚠️ Concerns & Risks

⚠️ Steep decline in COVID-19 product revenues, with Paxlovid sales down 95% operationally and Comirnaty sales down 34% operationally, creating a significant headwind for overall top-line growth.

⚠️ Reported a GAAP net loss of $248 million and a reported loss per share of $(0.04), primarily driven by $4.3 billion in non-cash intangible asset impairment charges, which indicates challenges with the valuation or performance of certain acquired assets.

⚠️ A Phase 3 clinical trial setback for sigvotatug vedotin in non-small cell lung cancer (NSCLC) failed to meet its primary endpoint of overall survival, representing a disappointment in a key pipeline area.

🔮 CEO / Management Guidance

Pfizer raised the midpoint of its full-year 2026 revenue guidance by $500 million, now expecting a range of $60.5 to $62.5 billion, primarily due to better-than-expected performance from its non-COVID product portfolio. The company reaffirmed its full-year 2026 Adjusted diluted EPS guidance in the range of $2.80 to $3.00, noting that this guidance absorbs an approximate $0.10 impact related to the Innovent Biologics, Inc. transaction. Management expressed continued confidence in the business's strength and ongoing progress with cost improvement initiatives.

💬 Key Quote

Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders. — Dr. Albert Bourla, Chairman and CEO

📅 Quarter-over-Quarter Comparison

Comparing Q2 FY2026 vs Q1 FY2026 All quarters →

Revenue $14.5B → $15.0B

EPS $0.47 → $0.77

Gross Margin 75.4% → 75.7%

Net Income $2.687B → -$248M

YoY Growth 2% → 1%

Sentiment 🟡 Neutral → 🟡 Neutral

🏢 About Pfizer Inc.

Pfizer Inc. (PFE) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

PFE NYSE Healthcare All Pfizer Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: Pharmaceuticals Earnings Report Strategic Growth Cost Optimization

📁 More from Pfizer Inc.

View all earnings summaries for Pfizer Inc. →